The PTP1B Inhibitor Trodusquemine (MSI-1436) Improves Glucose Uptake in Equine Metabolic Syndrome Affected Liver through Anti-Inflammatory and Antifibrotic Activity

Figure 5

MSI-1436 ameliorates liver glucose absorption and Glut-2 availability under EMS condition. (a) Western blot analysis of the liver Glut-2 protein level. Results were normalized to the expression of endogenous β-actin control. (b) Histograms showing D-glucose uptake by treated and untreated liver tissue. Representative data from three independent experiments are shown ± SD (n = 3). An asterisk () indicates a comparison among healthy, EMS, and EMS-treated groups.  < 0.05,  < 0.01, and  < 0.001. Eq Liver_HE: liver explants derived from healthy horses; Eq Liver_EMS: untreated liver explants derived from EMS horses. Eq Liver_EMS + 1 µM MSI-1436: liver explants derived from EMS horses and treated with 1 µM of MSI-1436 inhibitor.

(a)

(b)